St. Jude Medical officials have attested that the allegations made regarding the lack of security and safety of the manufacturer’s cardiac devices are “false and misleading.”
The Minnesota-based global medical device manufacturer saw its shares drop last week after a Muddy Waters Capital report noted demonstrations of cyber attacks to two of the company’s cardiac devices.
Specifically, the report from the short selling firm Muddy Waters said they have seen demonstrations of two types of cyber attacks against St. Jude’s implantable cardiac devices: a “crash” attack that causes cardiac devices to malfunction—including by apparently pacing at a potentially dangerous rate; and, a battery drain attack that could be particularly harmful to device dependent users. The report from Muddy Waters admitted that the firm has no experience in cybersecurity, but nonetheless was able replicate in-house key exploits that help to enable these attacks. As such, the firm said that the devices called into question should be “recalled and remediated.”
In a response to these claims, St. Jude’s fired back in an Aug. 26 statement. Regarding the “crashes,” St. Jude’s officials said that “The report has little detail on this simulation and includes many inconsistencies. In fact, the screenshot of the Merlin programmer in the Muddy Water report shows a device that is functioning normally.
And regarding the battery drain allegation, St. Jude said “The report claimed that the battery could be depleted at a 50-foot range. This is not possible since once the device is implanted into a patient, wireless communication has an approximate 7-foot range. This brings into question the entire testing methodology that has been used as the basis for the Muddy Waters Capital and MedSec report.”
St. Jude further said that its software has been evaluated and assessed by several independent organizations and researchers including Deloitte and Optiv. Its statement read, “Our top priority is to reassure our patients, caregivers and physicians that our devices are secure and to ensure ongoing access to the proven clinical benefits of remote monitoring.” It continued, “We recognize the importance of providing physicians with up-to-date and accurate information in a timely and responsible manner so that they can make informed patient care decisions. Our analysis reinforces the need for researchers and manufactures to work together to discuss and resolve potential issues together to avoid unnecessarily alarming patients.”
